EDİGER, D. Et Al. 2022. Efficacy of Omalizumab Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO). ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1 , 25-30.

EDİGER, D., ERBAY, M., & Seker, Ü., (2022). Efficacy of Omalizumab Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO). ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1, 25-30.

EDİGER, DANE, MÜGE ERBAY, And ÜMMÜHAN ŞEKER. "Efficacy of Omalizumab Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)," ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1, 25-30, 2022

EDİGER, DANE Et Al. "Efficacy of Omalizumab Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)." ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1, pp.25-30, 2022

EDİGER, D. ERBAY, M. And Seker, Ü. (2022) . "Efficacy of Omalizumab Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)." ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1, pp.25-30.

@article{article, author={DANE EDİGER Et Al. }, title={Efficacy of Omalizumab Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)}, journal={ASTIM ALLERJI IMMUNOLOJI}, year=2022, pages={25-30} }